Matches in Nanopublications for { ?s ?p "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP274846.RAQjdXJm7M-gNLzYuYn_D9pedq5SrD3SUB_PLsedQ2q1s130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP274846.RAQjdXJm7M-gNLzYuYn_D9pedq5SrD3SUB_PLsedQ2q1s130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP879622.RACM0uRawSDrKUebEWCUsuSbvsHSRTr7vW6pbF-Dr2LnI130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879622.RACM0uRawSDrKUebEWCUsuSbvsHSRTr7vW6pbF-Dr2LnI130_provenance.
- NP401792.RAS0dGSejgBvoiag-EeKFg5zBz-mmwdE8_rlKcc6xVGaA130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401792.RAS0dGSejgBvoiag-EeKFg5zBz-mmwdE8_rlKcc6xVGaA130_provenance.
- assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP879620.RAVNLrpIrucd_XdSrz_ZJ3_mgZZdaFQsjclKgknGrORoU130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879620.RAVNLrpIrucd_XdSrz_ZJ3_mgZZdaFQsjclKgknGrORoU130_provenance.
- NP879621.RAe8N0aIllF-z-Q8A8iSeojJNpIH1iIHSY74qffm1o8to130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879621.RAe8N0aIllF-z-Q8A8iSeojJNpIH1iIHSY74qffm1o8to130_provenance.
- NP401512.RAKVO84x_NFhq6yoFVbfJwL0ifCl2swpoXrRvBoZDuxg8130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401512.RAKVO84x_NFhq6yoFVbfJwL0ifCl2swpoXrRvBoZDuxg8130_provenance.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.